BSW Wealth Partners Makes New $324,000 Investment in ChromaDex Co. (NASDAQ:CDXC)

BSW Wealth Partners acquired a new stake in ChromaDex Co. (NASDAQ:CDXC - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 88,847 shares of the company's stock, valued at approximately $324,000. BSW Wealth Partners owned about 0.12% of ChromaDex as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Miracle Mile Advisors LLC purchased a new stake in shares of ChromaDex during the 2nd quarter worth approximately $27,000. The Manufacturers Life Insurance Company purchased a new stake in shares of ChromaDex during the 2nd quarter worth approximately $31,000. Merriman Wealth Management LLC purchased a new position in ChromaDex in the 2nd quarter valued at approximately $32,000. Lazard Asset Management LLC purchased a new position in ChromaDex in the 1st quarter valued at approximately $43,000. Finally, SG Americas Securities LLC purchased a new position in ChromaDex in the 1st quarter valued at approximately $54,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

Insider Transactions at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total transaction of $82,110.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.64% of the stock is currently owned by insiders.

ChromaDex Stock Performance

ChromaDex stock traded down $0.12 during mid-day trading on Monday, reaching $5.74. The company's stock had a trading volume of 3,892,471 shares, compared to its average volume of 492,245. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $6.18. The company has a market capitalization of $435.84 million, a P/E ratio of 597.60 and a beta of 1.88. The firm's fifty day moving average price is $3.53 and its two-hundred day moving average price is $3.23.

ChromaDex (NASDAQ:CDXC - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 5.06%. The firm had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same period last year, the firm earned ($0.01) EPS. On average, research analysts predict that ChromaDex Co. will post 0.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Monday.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.